A case between Supernus and Sage Chemical over the Parkinson’s disease drug Apokyn has far-reaching implications for patients, according to the US Federal Trade Commission. Sage’s generic version of the drug was approved in 2022, but patients could not access it because approval does not cover the injector pen, which is still patented by Supernus.
According to Nicole DeFeudis, “Sage and its partner TruPharma have since alleged that Supernus has acted unlawfully to delay or block generics to Apokyn, including through its control over the injector pen. While Supernus has filed a motion to dismiss the case, the FTC filed an amicus, or “friend of the court,” brief on Monday arguing that “there is a broader public interest in the legal issues this case presents.””
To read more, click here.
(Source: Endpoints News, March 21st, 2023)